Approval · Notice of Compliance 23121 · 2020
GABAPENTIN: Notice of Compliance 23121
Issued January 20, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23121
- Date
- January 20, 2020
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Labelling Only
- Reason
- Administrative: Licensing Agreement Between Two Companies, Revisions to the Product Monograph, Revisions to the inner and outer labels
- Canadian reference product
- NEURONTIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GABAPENTIN | 02431289 | Marketed |
| GABAPENTIN | 02431297 | Cancelled Post Market |
Medicinal ingredients
- GABAPENTIN 600 MG per TAB
- GABAPENTIN 800 MG per TAB